HeartSciences (HSCS) Net Equity Issued and Repurchased (2022 - 2025)

HeartSciences (HSCS) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $171276.0 the latest figure, recorded in Q2 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $171276.0 in Q2 2025, while the trailing twelve-month figure through Apr 2026 was $801276.0 (down 49.96% YoY) and the FY2026 annual result came in at $172839.0, down 84.94% from the prior year.
• Net Equity Issued and Repurchased eased to $171276.0 in Q2 2025 per HSCS's latest filing, from $369000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for HSCS reached as high as $5.2 million in Q3 2022 and fell as low as $171276.0 in Q2 2025.
• A 4-year average of $1.4 million and a median of $630000.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased slumped 84.6% — and 2024, when it tumbled 53.88%.
• Year by year, Net Equity Issued and Repurchased stood at $5.2 million in 2022, then plunged by 87.87% to $630000.0 in 2023, then tumbled by 41.43% to $369000.0 in 2024, then plunged by 53.58% to $171276.0 in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $171276.0, $369000.0, and $630000.0 for Q2 2025, Q3 2024, and Q4 2023 respectively.